Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Direct and indirect cost of urge urinary incontinence with and without pharmacotherapy.

Goren A, Zou KH, Gupta S, Chen C.

Int J Clin Pract. 2014 Mar;68(3):336-48. doi: 10.1111/ijcp.12301. Epub 2013 Dec 22.

PMID:
24372892
2.

Economic burden of urgency urinary incontinence in the United States: a systematic review.

Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I.

J Manag Care Pharm. 2014 Feb;20(2):130-40. Review.

3.

Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.

Qin L, Luo X, Zou KH, Snedecor SJ.

J Med Econ. 2016;19(3):229-35. doi: 10.3111/13696998.2015.1111893. Epub 2015 Nov 23.

PMID:
26488196
4.

Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.

Tang DH, Colayco DC, Khalaf KM, Piercy J, Patel V, Globe D, Ginsberg D.

BJU Int. 2014 Mar;113(3):484-91. doi: 10.1111/bju.12505.

5.

Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.

Chapple C, Schneider T, Haab F, Sun F, Whelan L, Scholfield D, Dragon E, Mangan E.

BJU Int. 2014 Sep;114(3):418-26. doi: 10.1111/bju.12678. Epub 2014 Jul 1.

6.

[Pharmacoeconomic study of using solifenacin for the treatment of urge urinary incontinence in patients with overactive bladder syndrome].

Avksent'eva MV, Gerasimova KV, Khachatrian GR, Frolov MIu, Omel'ianovskiĭ VV, Avksent'ev NA.

Urologiia. 2014 Sep-Oct;(5):56-8, 60-1. Russian.

PMID:
25807761
7.

The effect of hyperactive bladder severity on healthcare utilization and labor productivity.

Angulo JC, Brenes FJ, Ochayta D, Lizarraga I, Arumí D, Trillo S, Rejas J.

Actas Urol Esp. 2014 May;38(4):249-56. doi: 10.1016/j.acuro.2013.11.002. Epub 2014 Jan 23. English, Spanish.

PMID:
24462234
8.

Potential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladder.

Lee LK, Goren A, Zou KH, Odell K, Russell D, Araiza AL, Luo X.

Int J Clin Pract. 2016 Jan;70(1):66-81. doi: 10.1111/ijcp.12758. Epub 2015 Dec 9.

9.

Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity.

Tang DH, Colayco D, Piercy J, Patel V, Globe D, Chancellor MB.

BMC Neurol. 2014 Apr 4;14:74. doi: 10.1186/1471-2377-14-74.

10.

Impact of overactive bladder on work productivity.

Coyne KS, Sexton CC, Thompson CL, Clemens JQ, Chen CI, Bavendam T, Dmochowski R.

Urology. 2012 Jul;80(1):97-103. doi: 10.1016/j.urology.2012.03.039.

PMID:
22748868
11.

Global prevalence and economic burden of urgency urinary incontinence: a systematic review.

Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ.

Eur Urol. 2014 Jan;65(1):79-95. doi: 10.1016/j.eururo.2013.08.031. Epub 2013 Aug 27. Review.

PMID:
24007713
12.

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.

Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.

Curr Med Res Opin. 2009 Sep;25(9):2159-65. doi: 10.1185/03007990903103279.

PMID:
19601704
13.

Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder.

Jimenez-Cidre M, Costa P, Ng-Mak D, Sahai A, Degboe A, Smith CP, Tsai K, Herschorn S.

Curr Med Res Opin. 2014 Aug;30(8):1557-64. doi: 10.1185/03007995.2014.918028. Epub 2014 May 12.

PMID:
24762033
14.

Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial.

Dubeau CE, Kraus SR, Griebling TL, Newman DK, Wyman JF, Johnson TM 2nd, Ouslander JG, Sun F, Gong J, Bavendam T.

J Urol. 2014 Feb;191(2):395-404. doi: 10.1016/j.juro.2013.08.027. Epub 2013 Aug 21.

PMID:
23973522
15.

Effect of transobturator tape on overactive bladder symptoms and urge urinary incontinence in women with mixed urinary incontinence.

Tahseen S, Reid P.

Obstet Gynecol. 2009 Mar;113(3):617-23. doi: 10.1097/AOG.0b013e31819639e3.

PMID:
19300325
16.

Burden of illness associated with lower urinary tract symptoms including overactive bladder/urinary incontinence.

Kannan H, Radican L, Turpin RS, Bolge SC.

Urology. 2009 Jul;74(1):34-8. doi: 10.1016/j.urology.2008.12.077. Epub 2009 May 9.

PMID:
19428076
17.

Evaluating the health and economic impact of osteoarthritis pain in the workforce: results from the National Health and Wellness Survey.

Dibonaventura Md, Gupta S, McDonald M, Sadosky A.

BMC Musculoskelet Disord. 2011 Apr 28;12:83. doi: 10.1186/1471-2474-12-83.

18.

Estimated economic costs of overactive bladder in the United States.

Hu TW, Wagner TH, Bentkover JD, LeBlanc K, Piancentini A, Stewart WF, Corey R, Zhou SZ, Hunt TL.

Urology. 2003 Jun;61(6):1123-8.

PMID:
12809878
19.

Comorbidities and personal burden of urgency urinary incontinence: a systematic review.

Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I.

Int J Clin Pract. 2013 Oct;67(10):1015-33. doi: 10.1111/ijcp.12164. Review.

PMID:
24073974
20.

Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.

Angulo JC, Valpas A, Rejas J, Linden K, Kvasz M, Snedecor SJ.

Clin Drug Investig. 2014 May;34(5):297-307. doi: 10.1007/s40261-014-0178-1. Review.

PMID:
24567280

Supplemental Content

Support Center